Cwm LLC Boosts Stock Position in Merck & Co., Inc. $MRK

Cwm LLC grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 6.5% during the 4th quarter, HoldingsChannel reports. The fund owned 1,017,023 shares of the company’s stock after buying an additional 61,957 shares during the period. Cwm LLC’s holdings in Merck & Co., Inc. were worth $107,052,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in MRK. DLD Asset Management LP lifted its position in shares of Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after acquiring an additional 11,000,000 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Merck & Co., Inc. by 192.7% during the third quarter. Assenagon Asset Management S.A. now owns 5,496,664 shares of the company’s stock worth $461,335,000 after acquiring an additional 3,618,532 shares in the last quarter. Invesco Ltd. lifted its position in shares of Merck & Co., Inc. by 16.6% during the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after acquiring an additional 2,821,766 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after acquiring an additional 2,735,459 shares in the last quarter. Finally, Van ECK Associates Corp lifted its position in shares of Merck & Co., Inc. by 61.6% during the third quarter. Van ECK Associates Corp now owns 5,325,033 shares of the company’s stock worth $446,930,000 after acquiring an additional 2,029,342 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MRK shares. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $82.00 to $130.00 in a research report on Thursday, December 18th. Cantor Fitzgerald increased their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Citigroup increased their price objective on Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, March 20th. Finally, UBS Group increased their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average target price of $128.47.

Insiders Place Their Bets

In other news, CEO Robert M. Davis sold 47,434 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at approximately $52,362,780.08. This represents a 9.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the transaction, the executive vice president directly owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 320,176 shares of company stock valued at $38,281,735 over the last quarter. Insiders own 0.13% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA grants priority review to Merck and Daiichi’s BLA for ifinatamab deruxtecan in extensive-stage small cell lung cancer — this accelerates the regulatory timeline for a potentially material oncology asset and could add to future revenue if approved. MRK, Daiichi’s BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
• Positive Sentiment: UBS raised its price target on MRK to $145, signaling bullish analyst sentiment and providing support for longer‑term upside relative to current levels. UBS Group Boosts Merck & Co., Inc. (NYSE:MRK) Price Target to $145.00
• Positive Sentiment: Keytruda remains the primary growth driver (over half of pharma sales); analysts will be watching Q1 results and guidance for continued uptake from new indications — a clean print would likely stabilize the stock. Will Keytruda Continue to Aid Merck’s Top Line in Q1 Earnings?
• Neutral Sentiment: Options/technical coverage: a retail/options piece outlines a bullish diagonal trade targeting $130 by mid‑June — this reflects trader optimism but is speculative and not company‑fundamental. This Merck (MRK) stock bullish diagonal trade targets a price of $130 by June 18
• Neutral Sentiment: Industry tailwinds in animal health highlighted in a market report (Merck’s animal-health unit participates in this market), a long‑term positive structural theme but not an immediate catalyst. Animal Health Market Intelligence Report 2026-2034
• Neutral Sentiment: Coverage about Merck KGaA (XTRA:MRK) appears in the news stream — note this is a different company (German Merck), which can cause ticker confusion among retail investors but does not affect Merck & Co.’s fundamentals. Assessing Merck KGaA (XTRA:MRK) Valuation After Mixed Recent Share Performance And Healthcare Pipeline Developments
• Negative Sentiment: Media scrutiny of Merck’s patent strategies and pricing for Keytruda (USAToday feature) can increase regulatory and reputational risk; that scrutiny can weigh on sentiment and prompt selling or political/regulatory pressure. How Merck keeps prices for its blockbuster cancer drug sky high
• Negative Sentiment: Near‑term price weakness / market reaction: recent intraday moves show MRK underperforming broader indices, reflecting profit‑taking and caution ahead of earnings/updates. Merck (MRK) Stock Sinks As Market Gains: Here’s Why

Merck & Co., Inc. Trading Down 1.6%

Shares of MRK stock opened at $118.07 on Thursday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a market capitalization of $291.62 billion, a PE ratio of 16.22, a price-to-earnings-growth ratio of 2.41 and a beta of 0.26. The business’s fifty day moving average is $119.26 and its 200 day moving average is $105.51.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter last year, the business posted $1.72 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.